Biodeal Pharma lands Rs. 385 crore to fuel global CDMO push
What's the deal? Biodeal PharmaceuticalsDealroom has a profile for this one. Try Dealroom →, a specialty pharmaceutical Contract Development and Manufacturing Organisation (CDMO), has raised Rs. 385 crore (roughly $40 million) in growth equity from RMB CapitalworksDealroom has a profile for this one. Try Dealroom →. The investor is a joint venture between Rand Merchant BankDealroom has a profile for this one. Try Dealroom → and Capitalworks GroupDealroom has a profile for this one. Try Dealroom →.
What's the endgame? Biodeal, which has built a position in nasal drug delivery over more than two decades, serves clients across domestic and international markets. The company plans to strengthen its specialty pharmaceutical and manufacturing capabilities and expand its presence in regulated markets.
Where's the money going? The investment will support expansion across Asian markets while accelerating growth in the CIS, Latin America, Africa, and Europe. Biodeal also intends to keep progressing towards a planned public listing.
Why now? Biodeal has posted consistent profitable growth over the past five years. FY26 revenue is estimated to have grown by more than 60% year-on-year, alongside wider EBITDA margins.
What they're saying: "Healthcare is a core focus for us, and Biodeal fits our thesis of a differentiated player primed for rapid growth," said Anshuman Malur, managing partner at RMB Capitalworks. Chairman and managing director Anurag Kumar called the deal "a strong endorsement of the platform we have built over the past two decades."
The signal: Global drugmakers increasingly outsource specialised manufacturing to CDMO partners in regulated markets, and investors are backing niche players positioned to capture that demand. Biodeal's raise — sizeable for its category — reflects capital flowing towards focused pharmaceutical manufacturers with a clear export runway.
Read more: Indian Pharma Post
Image credit: Monash Public Library Service
